



**SHATTUCK**  
LABS

NEWS RELEASE

# Shattuck Labs Announces Participation in Upcoming March Conferences

2023-03-01

AUSTIN, TX and DURHAM, NC, March 01, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in two investor conferences in March 2023.

## Presentation Details

Conference: Cowen 43rd Annual Health Care Conference  
Format: Novel IO Panel Discussion  
Presenter: Dr. Lini Pandite, MBChB, M.B.A., Shattuck's Chief Medical Officer  
Date: March 6, 2023  
Time: 9:10-10:10 a.m. ET

Conference: Oppenheimer 33rd Annual Healthcare Conference  
Format: Corporate Presentation  
Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer  
Date: March 13, 2023  
Time: 2:00-2:30 p.m. ET

A live webcast of the panel discussion and presentation will be available on the Investors section of the Company's website. A replay of the webcasts will be archived for up to 90 days following the presentation date.

## About Shattuck Labs, Inc.

Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company's lead SL-172154 (SIRP $\alpha$ -Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize

the CD40 pathway, is being evaluated in multiple Phase 1 trials. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: [www.ShattuckLabs.com](http://www.ShattuckLabs.com).

The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.

**Investor & Media Contact:**

Conor Richardson  
Vice President of Investor Relations  
Shattuck Labs, Inc.  
[InvestorRelations@Shattucklabs.com](mailto:InvestorRelations@Shattucklabs.com)

Source: Shattuck Labs, Inc.